The application of the biological treatment in atopic dermatitis: focus on dupilumab

Y.S. Smolkin 1,2,3, S.S. Masalskiy 1,3, O.Y. Smolkina 3

1 Association Pediatric Allergist and Immunologist Russia
2 Academy Postgraduate Education «Federal State Budget Founding Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological Agency», Department of Clinical Immunology and Allergology
3 «Scientific-Clinical Consultative Center of Allergology and Immunology», Ltd.

ALLERGOLOGY AND IMMUNOLOGY IN PEDIATRICS, Volume 61 • Number 2 • June 2020, pp. 27 – 40
DOI: 10.24411/2500-1175-2020-10005

Atopic dermatitis (AD) significantly reduces the quality of life of patients. Skin lesions, itching, and sleep dysfunction lead to impaired social adaptation and work performance.
Systemic immunosuppressants are used for the treatment of severe AD. The use of antihistamines and antileukotrienes in the monotherapy or the combination with topical steroids is not recommended and not effective for treatment AD. This group of medicine drugs applied in the cases of the сo-morbidity with allergic rhinitis, food allergy and asthma.
If it is necessary to use systemic drugs for the treatment of severe dermatitis, the appointment of biological therapy (anti-IL4Rα) is recommended from the 12 years. Dupilumab has a high-efficiency profile (LIBERTY and ADOL study): by 12–16 weeks in children, about 80% of patients have an EASI index halved, about half of patients report a decrease in EASI<75% of the initial values. Dupilumab in recommended doses-200 mg (≤60 kg; ≤18 years) or 300 mg 2 times a month relieves skin lesions, itching and significantly improves the quality of life of patients. Serological markers of allergic inflammation (IgE, periostin, chemokine CCL17) are reduced during treatment.
Clinical studies (CHRONOS) showed no serious side effects and a decrease in the frequency of skin infections and herpetic eczema when using dupilumab, but a slight increase in the frequency of non-severe respiratory diseases and conjunctivitis. Conjunctivitis was not the cause of drug withdrawal according to research data. When co-morbidity dermatitis and asthma, dupilumab reduces the number of exacerbations of both diseases.
Other monoclonal antibodies (omalizumab, reslizumab, mepolizumab, benralizumab) are not effective for therapy allergic eczema.
Cyclosporin at a dose of 2.5–5 mg/kg/day has comparable effectiveness with dupilumab in the 2 weeks of administration. Then cyclosporin’s results get worse. Systemic side effects limit the use of cyclosporine for more than 8 weeks. Oral steroids can be prescribed in a short course for severe exacerbations (0.5–1 mg/kg/day, ≈ 1 week). Dupilumab is the drug of choice for systemic treatment of dermatitis in patients ≥12 years. The long-term safety-effectiveness profile of dupilumab is better than any other systemic treatment. The drug is used for any phenotype of dermatitis, independently of the increase in serum IgE.

  1. Smolkin Y.S., Balabolkin I.I., Gorlanov I.A. et al. Consensus document APAIR: atopic dermatitis in children — update 2019 (short version). Part 1. Allergol Immunol Pediatr. 2020; 60 (1): 4–25. doi:10.24411/2500-1175-2020-10001
  2. Furue M., Chiba T., Tsuji G. et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017; 66 (3): 398–403. doi:10.1016/J.ALIT.2016.12.002
  3. Tsakok T., Marrs T., Mohsin M. et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016; 137(4). doi:10.1016/j.jaci.2015.10.049
  4. Cabanillas B., Brehler A.C., Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017; 17 (4): 309–315. doi:10.1097/ACI.0000000000000376
  5. Eyerich S., Metz M., Bossios A., Eyerich K. New biological treatments for asthma and skin allergies. Allergy Eur J Allergy Clin Immunol. 2019; (June 2019): 546–560. doi:10.1111/all.14027
  6. Matterne U., Böhmer M.M., Weisshaar E., Jupiter A., Carter B., Apfelbacher C.J. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev. Published online January 22, 2019. doi:10.1002/14651858.CD012167.pub2
  7. Snast I., Reiter O., Hodak E., Friedland R., Mimouni D., Leshem Y.A. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2018; 19 (2): 145–165. doi:10.1007/s40257-017-0324-7
  8. Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018; 32: 657–682. doi:10.1111/jdv.14891
  9. Смирнов А.В., Трофименко И.И. Практические вопросы применения циклоспорина в лечении гломерулопатий. Нефрология. 2010; 14 (4): 92–102.
  10. Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema ? a systematic review and meta-analysis. J Eur Acad Dermatology Venereol. 2007;0(0):070206173308005-??? doi:10.1111/j.1468-3083.2006.02023.x
  11. Камашева Г.Р., Хакимова Р.Ф., Валиуллина С.А. Методы оценки степени тяжести атопического дерматита у детей раннего возраста. ЖурналЗемский врач.” 2010; 4: 32–34.
  12. Bachert C., Mannent L., Naclerio R.M. et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA – J Am Med Assoc. 2016; 315 (5): 469–479. doi:10.1001/jama.2015.19330
  13. Масальский С.С., Калмыкова А.А., Уханова О.П., Климов Л.Я., Разгуляева А.В. Обзор роли периостина — нового биологического маркера при бронхиальной астме. Российский аллергологический журнал. 2014; 6: 5–7.
  14. Масальский С.С., Калмыкова А.С., Уханова О.П., Смолкин Ю.С., Маркарова И.В., Такушинова Ф.М. Использование сывороточного периостина в качестве маркера обострений астмы у детей. Аллергология и иммунология в педиатрии. 2018; 4 (55): 37–48. doi:10.1016/j.jaci.2018.11.006
  15. Mishra S.K., Wheeler J.J., Ji R.-R., Ko M.-C. Correspondence TO. Periostin Activation of Integrin Receptors on Sensory Neurons Induces Allergic Itch. Published online 2020. doi:10.1016/j.celrep.2020.03.036
  16. Hamilton J.D., Chen Z., Beck L.A. et al. 1066 Biomarkers CCL17/TARC and total IgE do not predict clinical response to dupilumab in atopic dermatitis (AD): A post hoc analysis of pooled phase 3 data (SOLO 1 & 2). J Invest Dermatol. 2018; 138 (5): S181. doi:10.1016/j.jid.2018.03.1079
  17. Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014; 2014(1). doi:10.1002/14651858.CD003559.pub4
  18. Eyerich S., Metz M., Bossios A., Eyerich K. New biological treatments for asthma and skin allergies. 2020; (June 2019): 546–560. doi:10.1111/all.14027
  19. UKHANOVA O.P., DZHABAROVA A.A., SIVUN I.V., BURINDINA E.I. Perspectives of Genetically Engineered Therapy in Severe Seasonal Allergic Rhinitis. Bull Contemp Clin Med. 2018; 11 (2): 36–40. doi:10.20969/vskm.2018.11(2).36-40
  20. Uysal P., Eller E., Mortz C.G., Bindslev-Jensen C. An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized. J Allergy Clin Immunol. 2014; 133 (3). doi:10.1016/j.jaci.2013.10.015
  21. Wang H.H., Li Y.C., Huang Y.C. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol. 2016; 138 (6): 1719–1722.e1. doi:10.1016/j.jaci.2016.05.038
  22. Prussin C., Mathur S., Roufosse F. Targeting the interleukin-5 Pathway for Treatment of eosinophilic Conditions Other than Asthma. Article. 2018; 5: 1. doi:10.3389/fmed.2018.00049
  23. Weinstein S.F., Katial R., Jayawardena S. et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018; 142 (1): 171–177.e1. doi:10.1016/j.jaci.2017.11.051
  24. Guttman-Yassky E., Bissonnette R., Ungar B. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019; 143 (1): 155–172. doi:10.1016/j.jaci.2018.08.022
  25. Paller A.S., Bansal A., Simpson E.L. et al. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020; 21 (1): 119–131. doi:10.1007/s40257-019-00478-y
  26. Simpson E.L., Bieber T., Guttman-Yassky E. et al. Two Phase 3 Trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375 (24): 2335–2348. doi:10.1056/NEJMoa1610020
  27. Gooderham M.J., Hong H.C. ho, Eshtiaghi P., Papp K.A. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018; 78 (3): S28–S36. doi:10.1016/j.jaad.2017.12.022
  28. Carugno A., Raponi F., Locatelli A.G. et al. No evidence of increased risk for COVID‐19 infection in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area ‐ Bergamo, Lombardy, Italy. J Eur Acad Dermatology Venereol. Published online April 27, 2020:jdv.16552. doi:10.1111/jdv.16552
  29. Wollenberg A., Beck L.A., Blauvelt A. et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. Published online 2019: 1120–1135. doi:10.1111/bjd.18434
  30. Ariens L.F.M., Gadkari A., Van Os-Medendorp H. et al. Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: Indirect comparison using the Eczema Area and severity index. Acta Derm Venereol. 2019; 99 (10): 851–857. doi:10.2340/00015555-3219
  31. Sánchez-Ramón S., Eguíluz-Gracia I., Rodríguez-Mazariego M.E. et al. Sequential combined therapy with Omalizumab and Rituximab: A new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol. 2013; 23 (3): 190–196.
  32. Jacobi A., Antoni C., Manger B., Schuler G., Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005; 52 (3, Pt. 1): 522–526. doi:10.1016/j.jaad.2004.11.022
  33. Kabashima K., Furue M., Hanifin J.M. et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018; 142 (4): 1121–1130.e7. doi:10.1016/j.jaci.2018.03.018
  34. Guttman-Yassky E., Blauvelt A., Eichenfield L.F. et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatology. 2020; 156 (4). doi:10.1001/jamadermatol.2020.0079
  35. Pavord I., Ford L., Corren J. et al. Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 liberty asthma quest study. Thorax. 2018; 73 (Suppl 4): A121–A122. doi:10.1136/thorax-2018-212555.202

Smolkin YS, Masalskiy SS, Smolkina OY. The application of the biological treatment in atopic dermatitis: focus on dupilumab. Allergology and Immunology in Pediatrics. 2020;61(2):27-40. (In Russ.) https://doi.org/10.24411/2500-1175-2020-10005

For correspondense

Yury S. Smolkin, doctor of medical sciences, professor of Department of Clinical Immunology and Allergology Academy of postgraduate educational under FSBU FSCC of FMBA, vicepresident APAIR
ORCID ID: 0000-0001-7876-6258
Address: 6 Ostrovityanova Str., Moscow, 117513, Russia
E-mail: smolking@df.ru

ALLERGOLOGY and IMMUNOLOGY in PEDIATRICS

Spelling error report

The following text will be sent to our editors: